- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01500863
Endometrial Receptivity After GnRH Agonist Triggering (ERAMAD)
Endometrial Receptivity After GnRH Agonist Triggering From Final Oocyte Maturation
Conventional luteal phase support after human chorionic gonadotrophin (hCG) triggering in women undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) provides adequate pregnancy rates and live birth rates, but Ovarian hyperstimulation syndrome (OHSS) still occurs in 1-3% of the patients. If gonadotropin-releasing hormone agonist (GnRHa) are used instead of hCG, OHSS does not occur, but clinical results are somehow diminished.
By testing different luteal support protocols on women undergoing GnRHa triggering, the investigators aim to find out which protocol resembles the most the gene expression profile observed after hCG triggering and conventional luteal phase support, in order to choose it as the most adequate in terms of endometrium receptivity and safety (OHSS incidence).
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28035
- Instituto Valenciano de Infertilidad
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria :
- Healthy oocyte donor women
- Aged 18-35 years
- With a menstrual cycle length of 26-35 days
- Normal ultrasound scan of uterus and ovaries
- Normal basal hormones
- No contraindication for controlled ovarian stimulation (COS)
- Willing to participate in the study and providing written informed consent.
Exclusion Criteria:
- Subjects with current or previous history of an endocrine abnormality
- Subjects with an abnormal outcome of blood biochemistry or hematology
- Subjects with an abnormal cervical smear
- Subjects with a chronic disease
- Subjects with any relevant ovarian-, tubal- or uterine-pathology that could interfere with the COS treatment
- Pregnancy
- Subjects who had a previous history of ovarian hyperresponse or ovarian hyperstimulation syndrome (OHSS), polycystic ovary syndrome (PCOS) or a basal antral follicle count (AFC) of more than 20 on ultrasound (11 mm, both ovaries combined) .
- Previous low ovarian response to FSH or hMG treatment (i.e. cycle cancelled due to insufficient ovarian response or less than 6 oocytes obtained).
- A history of recurrent miscarriage,
- Smoking more than 10 cigarettes per day.
- Not willing to comply with study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: hCG
|
single shot of 6500 IU hCG s.c. at the time of triggering
|
Experimental: Triptorelin 0.2mg s.c.
|
single shot of 0.2mg triptorelin s.c. at the time of triggering
|
Experimental: 0.2mg triptorelin plus estradiol/progesterone
|
4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
|
Experimental: 0.2mg tripoterlin plus single bolus hCG 1500 IU
|
single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
|
Experimental: 0.2mg tripoterlin plus multiple boluses hCG 500 IU
|
single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
|
Experimental: 0.2mg tripoterlin plus multiple doses recLH
|
300 IU recombinant LH every 48h and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
endometrial receptivity gene expression profile
Time Frame: participants will be followed for the duration of the cycle, an expected average of 4 weeks
|
participants will be followed for the duration of the cycle, an expected average of 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of moderate/severe OHSS in all different treatment group
Time Frame: participants will be followed for the duration of the cycle, an expected average of 4 weeks
|
Mild OHSS Grade 1, abdominal distension and discomfort Grade 2, features of grade 1 plus nausea, vomiting and/or diarrhea; ovaries are enlarged from 5 to 12 cm Moderate OHSS Grade 3, features of mild OHSS plus ultrasonic evidence of ascites Severe OHSS Grade 4, features of moderate OHSS plus evidence of ascites and/or hydrothorax and breathing difficulties Grade 5, all of the above, plus change in the blood volume, increased blood viscosity due to hemoconcentration, coagulation abnormality, and diminished renal perfusion and function
|
participants will be followed for the duration of the cycle, an expected average of 4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Alfonso Bermejo, MD, IVI Madrid
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Ovarian Hyperstimulation Syndrome
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Estrogens
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptive Agents, Female
- Luteolytic Agents
- Progestins
- Estradiol
- Triptorelin Pamoate
- Progesterone
- Estradiol 17 beta-cypionate
- Estradiol 3-benzoate
- Polyestradiol phosphate
Other Study ID Numbers
- MAD-AB-ERA-2011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Hyperstimulation Syndrome
-
ART Fertility Clinics LLCTerminatedOvarian HyperstimulationUnited Arab Emirates
-
Ferring PharmaceuticalsCompletedOvarian Hyperstimulation Syndrome (OHSS)France
-
Benha UniversityCompletedOvarian HyperstimulationEgypt
-
Regionshospitalet Viborg, SkiveCompletedOHSS (Ovarian Hyperstimulation)Denmark
-
Bio Genuine (Shanghai) Biotech Co., Ltd.Not yet recruitingAssisted Reproductive Technology | Controlled Ovarian HyperstimulationChina
-
Wolfson Medical CenterWithdrawnAdministration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)
-
Etlik Zubeyde Hanim Womens' Health and Teaching...CompletedOvarian Hyperstimulation Syndrome | Polycystic Ovarian Syndrome
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingInfertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early OvulationChina
-
Royan InstituteCompletedOvarian Hyperstimulation SyndromeIran, Islamic Republic of
-
Royan InstituteCompletedPolycystic Ovary Syndrome | Ovarian Hyperstimulation SyndromeIran, Islamic Republic of
Clinical Trials on hCG
-
Royan InstituteCompletedInfertilityIran, Islamic Republic of
-
Wael Elbanna ClinicNational Research Centre, EgyptRecruitingStudy to Assess the Effect of Intrauterine Adminstration of HCG Versus Endometrial Injury by PipelleFemale InfertilityEgypt
-
Sohag UniversityRecruitingWoman With Tubal Ectopic PregnancyEgypt
-
Assaf-Harofeh Medical CenterUnknown
-
Assaf-Harofeh Medical CenterCompletedRetained Products of ConceptionIsrael
-
AZ Jan Palfijn GentOnze Lieve Vrouw HospitalCompletedInfertility | PCOSBelgium
-
IBSA Institut Biochimique SACompleted
-
Aristotle University Of ThessalonikiCompleted